28.11.2012 Views

Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...

Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...

Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

REFERENCES<br />

Tsang A. H. and Chung K. K. (2009) Oxidative and nitrosative <strong>stress</strong> <strong>in</strong> Park<strong>in</strong>son's disease.<br />

Biochim. Biophys. Acta. 1792, 643–650.<br />

Tsunoda M. and Sharma R. P. (1999) Altered dopam<strong>in</strong>e turnover <strong>in</strong> mur<strong>in</strong>e hypothalamus after<br />

low-dose cont<strong>in</strong>uous oral adm<strong>in</strong>istration <strong>of</strong> alum<strong>in</strong>um. J Trace Elem Med Biol 13:224–231.<br />

Turiault M., Parnaudeau S., Milet A., Parlato R., Rouzeau J. D., Lazar M. and Tronche F. (2007)<br />

Analysis <strong>of</strong> dopam<strong>in</strong>e transporter gene expression pattern – generation <strong>of</strong> DAT-iCre<br />

transgenic mice. FEBS J. 274, 3568–3577.<br />

Turski L., Bressler K., Rettig K. J., Loschmann P. A. and Wachtel H. (1991) Protection <strong>of</strong><br />

substantia nigra from MPP + <strong>neurotoxicity</strong> by Nmethyl- D-aspartate antagonists. Nature<br />

349, 414–418.<br />

Twelves D., Perk<strong>in</strong>s K. S. and Counsell C. (2003) Systematic review <strong>of</strong> <strong>in</strong>cidence studies <strong>of</strong><br />

Park<strong>in</strong>son’s disease. Mov. Disord. 18, 19–31.<br />

U. S. Public Health Service. (1992). ‘‘Toxicological Pr<strong>of</strong>ile for Alum<strong>in</strong>um and Compounds.’’<br />

(Contact No. 205-88-0608). Prepared by Clement International Corp.<br />

Uhl G. R., Hedreen J. C. and Price D. L. (1985) Park<strong>in</strong>son’s disease: loss <strong>of</strong> neurons from the<br />

ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35, 1215–<br />

1218.<br />

Uhl G. R., Walther D., Mash D., Faucheux B. and Javoy-Agid F. (1994) Dopam<strong>in</strong>e transporter<br />

messenger RNA <strong>in</strong> Park<strong>in</strong>son's disease and control substantia nigra neurons. Ann. Neurol.<br />

35, 494–498.<br />

Uitti R. J., Rajput A. H., Ahlskog J. E., Offord K. P., Schroeder D. R., Ho M. M., Prasad M., Rajput<br />

A. and Basran P. (1996) Amantad<strong>in</strong>e treatment is an <strong>in</strong>dependent predictor <strong>of</strong> improved<br />

survival <strong>in</strong> Park<strong>in</strong>son's disease. Neurology 46, 1551–1556.<br />

Uitti R. J., Baba Y., Wszolek Z. K. and Putzke D. J. (2005) Def<strong>in</strong><strong>in</strong>g the Park<strong>in</strong>son’s disease<br />

phenotype: <strong>in</strong>itial symptoms and basel<strong>in</strong>e characteristics <strong>in</strong> a cl<strong>in</strong>ical cohort. Park<strong>in</strong>sonism<br />

Relat. Disord. 11, 139–145.<br />

241

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!